☰

Carnamedica Sp. z o.o.

Scaling Class III production with auditable data

Industry
Medical Devices (Organ and Cell Preservation)
Headquarters
Warsaw, Poland
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Carnamedica Sp. z o.o.'s published strategy and is not endorsed by, or produced in cooperation with, Carnamedica Sp. z o.o.. Company website

Strategic priorities

Carnamedica Sp. z o.o. is a Warsaw-based manufacturer of Class III perfusion and preservation solutions for organ transplantation, including Belzer UW®, PumpProtect®, LungProtect® and CelProtect® products made in a GMP-certified facility. Reported net sales revenue grew 114.96% to 35,325,673 PLN in 2024, with total assets up 54.07% and net profit of 12,600,000 PLN, suggesting the operating base has moved into multi-market tendering rather than pilot supply.

The strategic priorities on the company side are three: hold MDR 2017/745 Class III compliance as the route to EU and Asian markets, extend the physician-founded R&D model (14+ years with transplant centres such as the Medical University of Warsaw) into a EU-funded 3.45 million PLN Smart Growth project on short- and long-term cell preservation, and keep 'Made in EU' cost optimisation as the differentiator against US and Japanese perfusion brands.

Each of those priorities depends on data the same way: the MDR Total Product Lifecycle requires continuous clinical evidence from the transplant centres that use the company's solutions; the Smart Growth project needs instrument-connected R&D data to optimise post-thaw cell viability; and a 114.96% revenue jump in one year means ERP, WMS, cold-chain and forecasting systems all have to absorb twice the volume on infrastructure sized for the previous year.

The opportunity sits in treating the digital layer as the shared substrate for those three priorities rather than as three parallel projects. Lot genealogy, clinical outcomes, R&D experiment data and distribution telemetry all carry audit-trail obligations under PN-EN ISO 13485 and MDR, which makes an evidence-by-design approach the lower-friction path for a company whose customers are procurement officers and notified bodies.

Challenges we see

  • Digital Integration

    Absorbing a doubling of revenue into existing operational systems

    Carnamedica moved from 16,433,324 PLN net sales revenue in 2023 to 35,325,673 PLN in 2024, a 114.96% increase with total assets up 54.07%, while keeping the GMP-certified aseptic filling line and Warsaw distribution at the centre of the operation. Multi-jurisdictional reporting now spans the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL), EU MDR and Asian regulatory frameworks.

    When manufacturing and distribution volume doubles in a single year, the systems that record batch genealogy, expiry and cold-chain status carry twice the load on infrastructure sized for the previous year, which moves reconciliation and ledger reconciliation onto the critical path before any new capacity is added.

  • Compliance Regulatory

    Maintaining MDR Total Product Lifecycle evidence across EU and Asian markets

    MDR 2017/745 requires a Total Product Lifecycle approach where clinical evidence is continuously updated after market entry, and Carnamedica's CE-marked Class III portfolio includes Belzer UW® cold-storage solution and PumpProtect®, LungProtect® and CelProtect® machine perfusion solutions sold into more than one regulatory jurisdiction.

    Where dossiers are updated per market by hand, the same evidence is re-typed into different submission structures each time a clinical or manufacturing change occurs, which makes the documentation cycle rather than the underlying technical work the binding constraint on releasing a change.

  • Operations Manufacturing

    Industrialising preservation-fluid R&D against an EU funding milestone

    The Smart Growth (NCBR Fast Track) project targets industrial-scale production technology for cell preservation fluids with improved post-thaw viability and reduced toxic cryoprotectant load, in collaboration with the Medical University of Warsaw, on a 3,450,197.09 PLN total budget and 2,070,118.25 PLN EU contribution.

    R&D that begins as small-batch formulation work and has to end as a manufactured product depends on experiment data moving from benchtop instruments into a queryable form, so formulation choices made during the project can be carried through to process scale-up with their evidence attached.

  • Operations Operations

    Coordinating a global cold chain with the manufacturing schedule

    Carnamedica distributes Class III perfusion solutions across the EU and into Asian markets, with batch-level lot genealogy, expiry control and temperature-sensitive handling requirements that have to be synchronised with the Warsaw manufacturing schedule and the public-procurement cycles in each receiving market.

    Where manufacturing and distribution are reconciled periodically rather than continuously, demand surprises in one market have to be absorbed by the next batch and the next tender rather than by an updated schedule, which tends to push safety stock up and service levels down at the same time.

  • Digital Integration

    Closing the loop between transplant centres and post-market surveillance

    MDR requires ongoing clinical evidence for Class III devices, including post-market clinical follow-up (PMCF), adverse-event reporting and outcome trend analysis sourced from the transplant centres using Carnamedica's solutions across multiple countries.

    When outcome data arrives from centres in different formats and on different cadences, the regulatory dossier and the company's own product-improvement loop both slow to the speed of the least-connected site, so post-market surveillance becomes a data-collection exercise rather than a learning one.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Putting GMP batch, lot and cold-chain data on one operations model

    Carnamedica's 114.96% revenue growth in 2024 doubled the volume on systems that record batch genealogy, expiry and stock rotation for Class III perfusion solutions. The new operating envelope is multi-market, with EU MDR, URPL and Asian framework reporting drawing on the same underlying inventory and lot record.

    An integrated ERP/WMS model with GS1 barcode capture, threshold-based replenishment, FIFO enforcement and an audit trail in ALCOA+ shape lets the same operational record serve manufacturing, distribution and URPL inspection, so the second year of growth is absorbed by the system rather than by manual reconciliation.

    • Carnamedica Sp. z o.o. financial filings, 2023-2024
    • Carnamedica operational footprint, carnamedica.com/aboutus/

  2. Unifying clinical, quality and regulatory evidence under MDR Total Product Lifecycle

    MDR 2017/745 requires clinical evidence to be updated continuously for Class III devices. Carnamedica's dossier set spans EU MDR, Polish URPL and Asian frameworks, and the CE-marked portfolio includes Belzer UW®, PumpProtect®, LungProtect® and CelProtect®.

    A quality management model that connects post-market clinical follow-up, change control, periodic review and multi-market submission records against one template, with literature surveillance and structured PMCF data captured at the source, lets the dossier be assembled from records rather than reconstructed for each submission cycle.

    • MDR 2017/745, Annex XIV on clinical evaluation and post-market clinical follow-up
    • PN-EN ISO 13485 quality management requirements for medical devices

  3. Connecting R&D instruments to a queryable cell-viability record

    The Smart Growth project's industrialisation of stem-cell preservation fluids relies on correlating solution composition parameters with post-thaw viability outcomes. Today, instrument readings from cell counters, osmometers and viability analysers are reconciled by hand against experimental notes.

    An instrument-connected laboratory data platform that captures results with method version, sample lineage and time-stamp attached, and exposes them through comparative dashboards, lets the R&D team move from 'reproducing the last successful formulation' to 'querying across every previous run' when the next composition decision is made.

    • Carnamedica Smart Growth project disclosure, NCBR Fast Track
    • Carnamedica product portfolio, carnamedica.com

  4. Linking cold-chain telemetry to manufacturing and tender scheduling

    Class III perfusion solutions move through EU and Asian markets on temperature-controlled logistics, and the public-procurement cycles in each receiving market impose their own demand pattern. Coordination today runs through periodic reconciliation between sales, manufacturing and freight partners.

    Cold-chain telemetry and shipment visibility feeding the same model as the manufacturing schedule lets forecast deviations in one market trigger a schedule adjustment in Warsaw while the batch is still being made, and lets tender-level commitments be checked against real inventory state before they are signed.

    • GS1 traceability guidance for medical devices
    • Carnamedica commercial footprint, carnamedica.com

  5. Capturing transplant-centre outcomes as data for PMCF and product improvement

    Post-market clinical follow-up under MDR depends on systematic outcome reporting from the transplant centres using Carnamedica's solutions. Currently the input arrives on different forms, on different cadences, and is reconciled into the PMCF record by the regulatory team.

    A clinical outcome registry with structured input for graft outcomes, adverse events and solution performance observations lets PMCF data arrive as records with audit trail attached, and feeds the same dataset into trend analysis that the product team reads as design input.

    • MDR 2017/745, Annex XIV, post-market clinical follow-up requirements
    • MEDDEV 2.12-1 vigilance guidance for medical devices

What we'd propose

  • Digital CDMO

    GMP-grade ERP and WMS operations platform

    We integrate Carnamedica's manufacturing, inventory and distribution data into one ALCOA+ audit-trail model with GS1 barcode capture, threshold-based replenishment and FIFO enforcement, so the same operational record serves the Warsaw line, EU distribution and Asian tenders, and the same record answers a URPL inspection on demand.

    • Lot genealogy and expiry engine

      One lot record across the chain

      Capture lot identity, raw-material genealogy, aseptic fill batch and expiry at every step through GS1 barcodes so the same lot record is visible from raw-material receipt through finished-goods dispatch and into the tender dossier, with audit entries that hold up under inspection.

    • Threshold-based replenishment

      Reorder driven by stock and demand state

      Configure multi-tier stock thresholds, predictive reorder calculations and integration with the manufacturing schedule so reorder decisions are made against live demand and tender-cycle state rather than against the last periodic review.

    • ALCOA+ audit trail and inspection view

      Evidence readable in inspection form

      Build the audit trail in ALCOA+ shape (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring and Available) so the operational record answers a URPL or notified-body question on its own, without a separate reconciliation step.

    • A 100%+ revenue increase is absorbed by the same operational system rather than by a parallel reconciliation process.
    • URPL, EU MDR and Asian inspections read from the same operational record instead of three reconstructed views.
    • Tender commitments can be checked against real lot and stock state at the moment they are signed.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Regulatory lifecycle management for Class III dossiers

    We connect post-market clinical follow-up, change control, periodic review and multi-market submission records against one quality management model, with structured PMCF input and literature surveillance built in, so a CE-marked Class III dossier is assembled from records rather than reconstructed for each submission.

    • Post-market clinical follow-up capture

      PMCF data as records

      Capture PMCF inputs (graft outcomes, adverse events, solution performance observations) with structured fields and audit trail attached, so the same data feeds the PMCF report under MDR Annex XIV and the internal product-improvement review without duplicate entry.

    • Change control with cross-document impact

      Scope of a change visible on day one

      Run impact analysis when a composition, process or specification change is proposed, retrieving every controlled document that references it so the update scope is known before the change control itself is approved.

    • Multi-market submission staging

      One document set, regional views

      Maintain the dossier as a single record set with regional requirement mapping and template variants for EU MDR, URPL and Asian frameworks, so the same evidence is published into the right structures without being reauthored each cycle.

    • Submission cycles draw from records that already exist, rather than triggering a fresh assembly exercise.
    • A standards or process change touches every dependent document, not only the one in the change-control form.
    • PMCF evidence arrives as data, which feeds both the regulatory report and the product design loop.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    R&D data platform for stem-cell preservation formulation work

    We connect cell counters, osmometers and viability analysers to a centralised time-series record with method version and sample lineage attached, and expose the data through comparative dashboards and 'golden batch' overlays, so the Smart Growth project's formulation decisions are made against the full experiment history.

    • Instrument integration

      Results captured at the bench

      Connect cell counters, osmometers and viability analysers through OPC UA (Open Platform Communications Unified Architecture) and vendor APIs so results land in the lab record with instrument identity, method version and time-stamp attached instead of being read off a screen and re-keyed.

    • Comparative formulation dashboard

      Every run against the reference

      Build interactive dashboards that overlay post-thaw viability outcomes across formulations with statistical comparison and 'golden batch' references, so each new formulation is judged against the full prior set rather than only the most recent run.

    • Sample lineage and batch record

      Each result traceable to its preparation

      Maintain the chain from preparation (composition, thaw protocol, operator) through analytical result and statistical outcome, so the R&D record is auditable end-to-end when the project moves from bench formulation into industrial process definition.

    • Formulation choices are made against every previous run, not only the one currently on the bench.
    • The instrument, method and operator behind every result are part of the record by construction.
    • The same dataset supports both the Smart Growth milestone reporting and the team's day-to-day formulation review.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Cold-chain and tender-aware demand visibility

    We link shipment telemetry, tender-cycle state and manufacturing schedule into a single visibility model, so demand changes in one market can trigger a Warsaw schedule adjustment while the batch is still being made, and tender commitments can be checked against real inventory state before they are signed.

    • Cold-chain telemetry ingestion

      Temperature and location as data

      Ingest temperature, humidity and location telemetry from shipment sensors so excursions are recorded as events on the lot record, not as separate paper trails, with automated deviation entries for the GMP and URPL audit trail.

    • Demand signal aggregation

      Tenders, sales orders and forecasts combined

      Combine current sales orders, tender pipeline and historical shipment patterns into one demand signal so the manufacturing schedule sees the next quarter at the resolution of the receiving market rather than the resolution of the last periodic review.

    • Manufacturing-schedule feedback

      Schedule adjusted against live state

      Surface forecast deviations and tender-pipeline changes to the manufacturing schedule so an unexpected demand move in one market triggers a schedule review while the current batch is still being made.

    • Demand surprises in one market are visible in the Warsaw schedule before the next batch is released.
    • Tender commitments are checked against real lot and stock state at the moment they are signed.
    • Cold-chain excursions are part of the lot record, not a parallel paper trail.

    We've done this before

    See how we do Enterprise AI
  • Enterprise AI

    Clinical outcome registry for transplant-centre PMCF

    We build a structured post-market clinical follow-up registry with adverse-event handling and product-trend analytics, so PMCF inputs arrive as records with audit trail attached and the same data feeds both the regulatory PMCF report and the internal product-improvement loop.

    • Centre-facing outcome capture

      Lower the reporting burden

      Provide a structured input surface for transplant centres to record graft outcomes, adverse events and solution performance observations, with method behind the data capture chosen to fit the centre's existing workflow so the data arrives in a consistent shape.

    • Adverse-event and vigilance workflow

      From report to notification

      Route adverse-event reports through severity classification, root-cause capture and regulatory notification triggers, so the same record supports the vigilance workflow under MEDDEV 2.12-1 and the internal quality review.

    • Product-trend analytics

      Outcome signals as design input

      Run statistical process control across product lines, regions and clinical applications, with trend detection against the baseline so a shift in outcomes is visible before it is large enough to drive a regulatory action.

    • PMCF evidence arrives as data, with audit trail in place, instead of being reconstructed for each reporting cycle.
    • Adverse-event handling is one workflow from centre input to regulatory notification, with the same record feeding the internal review.
    • Trend analysis turns the registry from a regulatory artefact into a stream of design input for the product team.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Carnamedica Sp. z o.o.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Operations data integration 35 → 80
A 114.96% revenue increase in 2024 landed on operational systems sized for the prior year. Lot genealogy, expiry, FIFO and audit-trail obligations now span EU and Asian markets from one Warsaw manufacturing base, which makes a unified ERP and WMS record the lowest-friction place to take the next step.
Regulatory digitisation 40 → 85
PN-EN ISO 13485 and MDR 2017/745 Class III are in place, but the dossier set still draws on different document systems across EU MDR, URPL and Asian frameworks. Total Product Lifecycle evidence under Annex XIV is the design principle that pulls those systems onto one platform.
Laboratory informatics 30 → 75
The Smart Growth project's industrialisation of stem-cell preservation fluids depends on correlating solution parameters with post-thaw viability outcomes. R&D data is currently reconciled by hand from instrument readings and lab notes, which is the gap the platform is designed to close.
Supply chain visibility 35 → 80
EU and Asian distribution with public-procurement cycles in each receiving market creates demand signal timing that the manufacturing schedule cannot yet see in real time. Cold-chain telemetry and shipment visibility are the practical routes into that gap.
Clinical data management 25 → 70
Post-market clinical follow-up under MDR Annex XIV is currently sourced from transplant centres through manual or semi-structured reporting, which is the long pole on both the regulatory report and the internal product-improvement loop.
Process automation 40 → 75
GMP-certified aseptic filling is the production baseline. The opportunity is to carry the audit trail, threshold logic and routing decisions out of the operator's notes and into the system, so the next capacity increment does not require a proportional addition to the manual reconciliation workload.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Carnamedica Sp. z o.o., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].